{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T22:37:28Z","timestamp":1776724648265,"version":"3.51.2"},"reference-count":68,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Clinics of North America"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.pcl.2023.12.001","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T19:23:13Z","timestamp":1704396193000},"page":"283-299","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Psychopharmacology Management in Autism Spectrum Disorder"],"prefix":"10.1016","volume":"71","author":[{"given":"Jay A.","family":"Salpekar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Scahill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcl.2023.12.001_bib1","doi-asserted-by":"crossref","unstructured":"APA. Diagnostic and statistical manual of mental disorders. 5th edition. American Psychiatric Association; 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"issue":"1","key":"10.1016\/j.pcl.2023.12.001_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0269881117741766","article-title":"Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology","volume":"32","author":"Howes","year":"2018","journal-title":"J\u00a0Psychopharmacol"},{"issue":"3","key":"10.1016\/j.pcl.2023.12.001_bib3","first-page":"245","article-title":"The Disrupted Connectivity Hypothesis of Autism Spectrum Disorders: Time for the Next Phase in Research","volume":"1","author":"Vasa","year":"2016","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"issue":"4","key":"10.1016\/j.pcl.2023.12.001_bib4","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1192\/bjp.bp.111.105551","article-title":"Intellectual disability and major psychiatric disorders: a continuum of neurodevelopmental causality. Comment Editorial","volume":"200","author":"Owen","year":"2012","journal-title":"Br J Psychiatry"},{"issue":"2","key":"10.1016\/j.pcl.2023.12.001_bib5","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/aur.2875","article-title":"Increased resting-state thalamocortical functional connectivity in children and young adults with autism spectrum disorder","volume":"16","author":"Baran","year":"2023","journal-title":"Autism Res"},{"issue":"2","key":"10.1016\/j.pcl.2023.12.001_bib6","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/YCO.0000000000000392","article-title":"Neuropsychiatric effects of epilepsy in developmental disorders","volume":"31","author":"Salpekar","year":"2018","journal-title":"Curr Opin Psychiatr"},{"key":"10.1016\/j.pcl.2023.12.001_bib7","first-page":"1","article-title":"Epilepsy in patients with autism: links, risks and treatment challenges","volume":"14","author":"Besag","year":"2018","journal-title":"Neuropsychiatric Dis Treat"},{"issue":"2","key":"10.1016\/j.pcl.2023.12.001_bib8","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/s41380-022-01860-9","article-title":"Glutamatergic synapse in autism: a complex story for a complex disorder","volume":"28","author":"Galineau","year":"2023","journal-title":"Mol Psychiatr"},{"key":"10.1016\/j.pcl.2023.12.001_bib9","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.neubiorev.2016.12.036","article-title":"Features of the broader autism phenotype in people with epilepsy support shared mechanisms between epilepsy and autism spectrum disorder","volume":"75","author":"Richard","year":"2017","journal-title":"Neurosci Biobehav Rev"},{"issue":"1","key":"10.1016\/j.pcl.2023.12.001_bib10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1176\/jnp.17.1.29","article-title":"The overt aggression scale for rating aggression in outpatient youth with autistic disorder: preliminary findings","volume":"17","author":"Hellings","year":"2005","journal-title":"J\u00a0Neuropsychiatry Clin Neurosci. Winter"},{"issue":"3","key":"10.1016\/j.pcl.2023.12.001_bib11","first-page":"283","article-title":"The Aberrant Behavior Checklist-Community: factor validity and effect of subject variables for adults in group homes","volume":"100","author":"Aman","year":"1995","journal-title":"Am J Ment Retard"},{"issue":"12","key":"10.1016\/j.pcl.2023.12.001_bib12","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1007\/s10803-022-05750-5","article-title":"Development and Psychometric Evaluation of the Open-Source Challenging Behavior Scale (OS-CBS)","volume":"3","author":"Frazier","year":"2023","journal-title":"J Autism Dev Disord"},{"issue":"5","key":"10.1016\/j.pcl.2023.12.001_bib13","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jaac.2016.02.016","article-title":"Weight Gain and Metabolic Consequences of Risperidone in Young Children With Autism Spectrum Disorder","volume":"55","author":"Scahill","year":"2016","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.pcl.2023.12.001_bib14","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJMoa013171","article-title":"Risperidone in Children with Autism and Serious Behavioral Problems","volume":"347","author":"Network RUoPPA","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.pcl.2023.12.001_bib15","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1001\/archgenpsychiatry.2009.30","article-title":"Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism","volume":"66","author":"King","year":"2009","journal-title":"Arch Gen Psychiatr"},{"issue":"2","key":"10.1016\/j.pcl.2023.12.001_bib16","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1177\/1362361315574889","article-title":"Sensitivity of the modified Children's Yale-Brown Obsessive Compulsive Scale to detect change: Results from two multi-site trials","volume":"20","author":"Scahill","year":"2016","journal-title":"Autism"},{"issue":"3","key":"10.1016\/j.pcl.2023.12.001_bib17","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1515\/ijamh.2011.039","article-title":"Psychopharmacological treatment of ADHD symptoms in children with autism spectrum disorder","volume":"23","author":"Handen","year":"2011","journal-title":"Int J Adolesc Med Health"},{"issue":"11","key":"10.1016\/j.pcl.2023.12.001_bib18","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/archpsyc.62.11.1266","article-title":"Research Units on Pediatric Psychopharmacology Autism N. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity","volume":"62","year":"2005","journal-title":"Arch Gen Psychiatr"},{"issue":"12","key":"10.1016\/j.pcl.2023.12.001_bib19","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1176\/appi.ajp.2015.15010055","article-title":"Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder","volume":"172","author":"Scahill","year":"2015","journal-title":"Am J Psychiatr"},{"issue":"3","key":"10.1016\/j.pcl.2023.12.001_bib20","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1089\/cap.2005.15.452","article-title":"Autism spectrum traits in children with mood and anxiety disorders","volume":"15","author":"Towbin","year":"2005","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"9","key":"10.1016\/j.pcl.2023.12.001_bib21","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.jaac.2018.10.016","article-title":"Development of the Parent-Rated Anxiety Scale for Youth With Autism Spectrum Disorder","volume":"58","author":"Scahill","year":"2019","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.pcl.2023.12.001_bib22","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.yebeh.2014.09.081","article-title":"Sleep, epilepsy, and autism","volume":"47","author":"Accardo","year":"2015","journal-title":"Epilepsy Behav"},{"issue":"Pt 5","key":"10.1016\/j.pcl.2023.12.001_bib23","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/brain\/awh425","article-title":"Atypical sleep architecture and the autism phenotype","volume":"128","author":"Limoges","year":"2005","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.pcl.2023.12.001_bib24","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/npp.2009.202","article-title":"Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders","volume":"35","author":"Hollander","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.pcl.2023.12.001_bib25","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1089\/cap.2005.15.682","article-title":"A\u00a0double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders","volume":"15","author":"Hellings","year":"2005","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"6","key":"10.1016\/j.pcl.2023.12.001_bib26","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/01.yic.0000224787.13782.0f","article-title":"Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study","volume":"21","author":"Wasserman","year":"2006","journal-title":"Int Clin Psychopharmacol"},{"issue":"2","key":"10.1016\/j.pcl.2023.12.001_bib27","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1023\/A:1010799115457","article-title":"Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial","volume":"31","author":"Belsito","year":"2001","journal-title":"J\u00a0Autism Dev Disord"},{"issue":"7","key":"10.1016\/j.pcl.2023.12.001_bib28","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.pnpbp.2010.07.005","article-title":"Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder","volume":"34","author":"Rezaei","year":"2010","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"1","key":"10.1016\/j.pcl.2023.12.001_bib29","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/00004583-199801000-00022","article-title":"\"Multidimensionally impaired disorder\": is it a variant of very early-onset schizophrenia?","volume":"37","author":"Kumra","year":"1998","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.pcl.2023.12.001_bib30","doi-asserted-by":"crossref","first-page":"662093","DOI":"10.3389\/fpsyt.2021.662093","article-title":"Neurodevelopmental Trajectories and Clinical Profiles in a Sample of Children and Adolescents With Early- and Very-Early-Onset Schizophrenia","volume":"12","author":"Pontillo","year":"2021","journal-title":"Front Psychiatr"},{"issue":"2","key":"10.1016\/j.pcl.2023.12.001_bib31","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1023\/A:1005451304303","article-title":"Assessment in multisite randomized clinical trials of patients with autistic disorder: the Autism RUPP Network. Research Units on Pediatric Psychopharmacology","volume":"30","author":"Arnold","year":"2000","journal-title":"J\u00a0Autism Dev Disord"},{"issue":"1","key":"10.1016\/j.pcl.2023.12.001_bib32","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S1056-4993(18)30142-1","article-title":"Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Background and rationale for an initial controlled study of risperidone","volume":"9","author":"McDougle","year":"2000","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"issue":"12","key":"10.1016\/j.pcl.2023.12.001_bib33","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1097\/CHI.0b013e3181bfd669","article-title":"Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial","volume":"48","author":"Aman","year":"2009","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"2","key":"10.1016\/j.pcl.2023.12.001_bib34","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jaac.2011.11.010","article-title":"Effects of risperidone and parent training on adaptive functioning in children with pervasive developmental disorders and serious behavioral problems","volume":"51","author":"Scahill","year":"2012","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"11","key":"10.1016\/j.pcl.2023.12.001_bib35","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.jaac.2012.08.028","article-title":"Research Units of Pediatric Psychopharmacology (RUPP) autism network randomized clinical trial of parent training and medication: one-year follow-up","volume":"51","author":"Arnold","year":"2012","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"6","key":"10.1016\/j.pcl.2023.12.001_bib36","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1542\/peds.2008-3782","article-title":"Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder","volume":"124","author":"Owen","year":"2009","journal-title":"Pediatrics"},{"issue":"11","key":"10.1016\/j.pcl.2023.12.001_bib37","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/CHI.0b013e3181b76658","article-title":"A\u00a0placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder","volume":"48","author":"Marcus","year":"2009","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"5","key":"10.1016\/j.pcl.2023.12.001_bib38","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1089\/cap.2006.16.541","article-title":"A\u00a0double-blind placebo-controlled pilot study of olanzapine in childhood\/adolescent pervasive developmental disorder","volume":"16","author":"Hollander","year":"2006","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"4","key":"10.1016\/j.pcl.2023.12.001_bib39","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s10803-015-2628-x","article-title":"Lurasidone for the Treatment of Irritability Associated with Autistic Disorder","volume":"46","author":"Loebel","year":"2016","journal-title":"J\u00a0Autism Dev Disord"},{"issue":"3","key":"10.1016\/j.pcl.2023.12.001_bib40","doi-asserted-by":"crossref","first-page":"407","DOI":"10.4088\/JCP.v67n0311","article-title":"Selective serotonin reuptak inhibitors in autism: a review of efficacy and tolerability","volume":"67","author":"Kolevzon","year":"2006","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"3","key":"10.1016\/j.pcl.2023.12.001_bib41","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/sj.npp.1300627","article-title":"A\u00a0placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism","volume":"30","author":"Hollander","year":"2005","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"10.1016\/j.pcl.2023.12.001_bib42","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jama.290.8.1033","article-title":"Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials","volume":"290","author":"Wagner","year":"2003","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.pcl.2023.12.001_bib43","doi-asserted-by":"crossref","first-page":"874","DOI":"10.4088\/JCP.v67n0603","article-title":"Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study","volume":"67","author":"Brawman-Mintzer","year":"2006","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"4","key":"10.1016\/j.pcl.2023.12.001_bib44","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/01.chi.0000153229.80215.a0","article-title":"An open-label trial of escitalopram in pervasive developmental disorders","volume":"44","author":"Owley","year":"2005","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"10.1016\/j.pcl.2023.12.001_bib45","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.pediatrneurol.2014.09.017","article-title":"A\u00a0randomized double-blind placebo-controlled clinical trial of adjuvant buspirone for irritability in autism","volume":"52","author":"Ghanizadeh","year":"2015","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.pcl.2023.12.001_bib46","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jpeds.2015.11.033","article-title":"Efficacy of Low-Dose Buspirone for Restricted and Repetitive Behavior in Young Children with Autism Spectrum Disorder: A Randomized Trial","volume":"170","author":"Chugani","year":"2016","journal-title":"J\u00a0Pediatr"},{"issue":"3","key":"10.1016\/j.pcl.2023.12.001_bib47","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S2215-0366(22)00436-9","article-title":"Catatonia in neurodevelopmental disorders: assessing catatonic deterioration from baseline","volume":"10","author":"Hauptman","year":"2023","journal-title":"Lancet Psychiatr"},{"issue":"1","key":"10.1016\/j.pcl.2023.12.001_bib48","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1192\/j.eurpsy.2021.2259","article-title":"Catatonia in autism spectrum disorders: A systematic review and meta-analysis","volume":"65","author":"Vaquerizo-Serrano","year":"2021","journal-title":"Eur Psychiatr"},{"issue":"4","key":"10.1016\/j.pcl.2023.12.001_bib49","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-1682","article-title":"ADHD Diagnosis and Treatment Guidelines: A Historical Perspective","volume":"144","author":"Wolraich","year":"2019","journal-title":"Pediatrics"},{"key":"10.1016\/j.pcl.2023.12.001_bib50","doi-asserted-by":"crossref","first-page":"212286","DOI":"10.7573\/dic.212286","article-title":"Alpha-2 receptor agonists for the treatment of posttraumatic stress disorder","volume":"4","author":"Belkin","year":"2015","journal-title":"Drugs Context"},{"issue":"4","key":"10.1016\/j.pcl.2023.12.001_bib51","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1089\/cap.2012.0119","article-title":"An open-label study of guanfacine extended release for traumatic stress related symptoms in children and adolescents","volume":"23","author":"Connor","year":"2013","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"1","key":"10.1016\/j.pcl.2023.12.001_bib52","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1056-4993(18)30137-8","article-title":"Pharmacologic treatment of tic disorders","volume":"9","author":"Scahill","year":"2000","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"key":"10.1016\/j.pcl.2023.12.001_bib53","series-title":"Textbook of autism spectrum disorders","first-page":"512","article-title":"Treating Hyperactivity in Children with Pervasive Developmental Disorders","author":"Scahill","year":"2022"},{"issue":"11","key":"10.1016\/j.pcl.2023.12.001_bib54","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.jaac.2015.08.013","article-title":"Atomoxetine, Parent Training, and Their Combination in Children With Autism Spectrum Disorder and Attention-Deficit\/Hyperactivity Disorder","volume":"54","author":"Handen","year":"2015","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"5","key":"10.1016\/j.pcl.2023.12.001_bib55","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1089\/cap.2012.0096","volume":"23","author":"Pearson","year":"2013","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"6","key":"10.1016\/j.pcl.2023.12.001_bib56","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.ridd.2014.03.006","article-title":"A\u00a0review of atomoxetine effects in young people with developmental disabilities","volume":"35","author":"Aman","year":"2014","journal-title":"Res Dev Disabil"},{"issue":"8","key":"10.1016\/j.pcl.2023.12.001_bib57","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1038\/s41386-018-0039-3","article-title":"A\u00a0randomized, placebo-controlled trial of extended-release guanfacine in children with autism spectrum disorder and ADHD symptoms: an analysis of secondary outcome measures","volume":"43","author":"Politte","year":"2018","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.pcl.2023.12.001_bib58","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jaac.2022.03.033","article-title":"Systematic Review and Meta-analysis: Efficacy of Pharmacological Interventions for Irritability and Emotional Dysregulation in Autism Spectrum Disorder and Predictors of Response","volume":"62","author":"Salazar de Pablo","year":"2023","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"16","key":"10.1016\/j.pcl.2023.12.001_bib59","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1056\/NEJMoa2103583","article-title":"Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder","volume":"385","author":"Sikich","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.pcl.2023.12.001_bib60","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1345\/aph.1G499","article-title":"Efficacy and safety of naltrexone use in pediatric patients with autistic disorder","volume":"40","author":"Elchaar","year":"2006","journal-title":"Ann Pharmacother"},{"issue":"3","key":"10.1016\/j.pcl.2023.12.001_bib61","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1089\/cap.1993.3.157","article-title":"Cardiovascular and other physical effects of acute administration of naltrexone in autistic children","volume":"3","author":"Herman","year":"1993","journal-title":"J\u00a0Child Adolesc Psychopharmacol. Fall"},{"issue":"1","key":"10.1016\/j.pcl.2023.12.001_bib62","first-page":"55","article-title":"Amantadine: a review of use in child and adolescent psychiatry","volume":"22","author":"Hosenbocus","year":"2013","journal-title":"Journal of the Canadian Academy of Child and Adolescent Psychiatry"},{"issue":"4","key":"10.1016\/j.pcl.2023.12.001_bib63","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/HTR.0000000000000709","article-title":"Prescribing Patterns of Amantadine During Pediatric Inpatient Rehabilitation After Traumatic Brain Injury: A Multicentered Retrospective Review From the Pediatric Brain Injury Consortium","volume":"37","author":"McLaughlin","year":"2022","journal-title":"J\u00a0Head Trauma Rehabil"},{"issue":"6","key":"10.1016\/j.pcl.2023.12.001_bib64","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1097\/00004583-200106000-00009","article-title":"Case series: amantadine open-label treatment of impulsive and aggressive behavior in hospitalized children with developmental disabilities","volume":"40","author":"King","year":"2001","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"6","key":"10.1016\/j.pcl.2023.12.001_bib65","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/WNF.0b013e3182a9339d","article-title":"Double-blind, placebo-controlled trial of risperidone plus amantadine in children with autism: a 10-week randomized study","volume":"36","author":"Mohammadi","year":"2013","journal-title":"Clin Neuropharmacol"},{"issue":"8","key":"10.1016\/j.pcl.2023.12.001_bib66","first-page":"CD013845","article-title":"Memantine for autism spectrum disorder","volume":"8","author":"Brignell","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pcl.2023.12.001_bib67","doi-asserted-by":"crossref","first-page":"108205","DOI":"10.1016\/j.yebeh.2021.108205","article-title":"Cross-sectional and longitudinal evaluation of cannabidiol (CBD) product use and health among people with epilepsy","volume":"122","author":"Strickland","year":"2021","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.pcl.2023.12.001_bib68","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.pediatrneurol.2022.10.014","article-title":"Cannabidiol Treatment for Neurological, Cognitive, and Psychiatric Symptoms in Sturge-Weber Syndrome","volume":"139","author":"Smegal","year":"2023","journal-title":"Pediatr Neurol"}],"container-title":["Pediatric Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031395523001773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031395523001773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T17:29:43Z","timestamp":1758475783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031395523001773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":68,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0031395523001773"],"URL":"https:\/\/doi.org\/10.1016\/j.pcl.2023.12.001","relation":{},"ISSN":["0031-3955"],"issn-type":[{"value":"0031-3955","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psychopharmacology Management in Autism Spectrum Disorder","name":"articletitle","label":"Article Title"},{"value":"Pediatric Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcl.2023.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}